证券代码：300573 证券简称：兴齐眼药 公告编号：2025-057 沈阳兴齐眼药股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长刘继东先生召集，会议通知于 2025 年 11 月 14 日通 过电子邮件等形式送达至各位董事，董事会会议通知中包括会议的相关资料，同 时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 11 月 17 日在公司会议室以现场与通讯会议相结合 的方式召开。 3、本次董事会应到 9 人，实际出席会议人数为 9 人。 4、本次董事会由董事长刘继东先生主持，公司高级管理人员列席了本次董 事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 根据相关法律、法规和规范性文件的规定，公司对截至 2025 年 9 月 30 日的 前次募集资金使用情况编制了《沈阳兴齐眼药股份有限公司前次募集资金使用情 况报告》；立信会计师事务所（特殊普通合伙）对《沈阳兴 ...

沈阳兴齐眼药股份有限公司 截至 2025 年 9 月 30 日止 前次募集资金使用情况报告 沈阳兴齐眼药股份有限公司 截至2025年9月30日止 前次募集资金使用情况报告 根据中国证券监督管理委员会《监管规则适用指引——发行类第7号》的相关规定，本公司将 截至2025年9月30日止前次募集资金使用情况报告如下： 一、 前次募集资金基本情况 前次募集资金的数额、资金到账时间 经中国证券监督管理委员会证监许可[2021]1343 号文批准，公司向特定对象发行人 民币普通股 5,763,282 股，募集资金总额为人民币 599,669,492.10 元，实际收到募集 资金为人民币 581,870,425.73 元（已扣除承销费用（含增值税））。上述募集资金于 2021 年 12 月 22 日全部到位，相应实收情况已经立信会计师事务所（特殊普通合伙） 审验，并出具信会师报字[2021]第 ZA15987 号验资报告。 截至 2025 年 9 月 30 日止，前次募集资金在银行募集资金专户的存储情况如下： 单位：人民币元 | 开户银行 | 账号 | 初始存放金额 | 截止日余额 | 备注 | | --- | --- | ...

目 录 页 次 | 一、 | 非经常性损益明细表鉴证报告 | 1-2 | | --- | --- | --- | | 二、 | 非经常性损益明细表 | 1-3 | 2022 年度、2023 年度、2024 年度及 截至 2025 年 9 月 30 日止 9 个月期间 非经常性损益明细表及鉴证报告 非经常性损益明细表鉴证报告 沈阳兴齐眼药股份有限公司 信会师报字[2025]第 ZA15155 号 沈阳兴齐眼药股份有限公司全体股东： 我们接受委托，对后附的沈阳兴齐眼药股份有限公司（以下简称 "贵公司"）2022 年度、2023 年度、2024 年度及截至 2025 年 9 月 30 日止 9 个月期间的非经常性损益明细表（以下简称"非经常性损 益明细表"）执行了合理保证的鉴证业务。 一、管理层对非经常性损益明细表的责任 贵公司管理层负责按照中国证券监督管理委员会颁布的《公开发 行证券的公司信息披露解释性公告第 1 号——非经常性损益（2008 年修订）》的相关规定编制 2022 年度非经常性损益明细表，按照中 国证券监督管理委员会颁布的《公开发行证券的公司信息披露解释性 公告第 1 号——非经常性损益（2023 ...

Core Insights - The overall myopia rate among children and adolescents in China reached 51.9% in 2022, with specific rates of 14.5% for 6-year-olds, 36% for elementary school students, 71.6% for middle school students, and 81% for high school students [2] Company Strategy - The company aims to raise awareness of its treatment plan to over 20 million people and ensure that over 1 million children receive timely and appropriate medication this year [2] - The company will implement a comprehensive multi-channel sales strategy, focusing on collaboration with retail channels and continuing academic promotion to build a network for myopia prevention and control [2]

Core Viewpoint - The company is focusing on a multi-channel marketing strategy to enhance the accessibility and patient experience of its atropine product, which is primarily sold through offline channels, accounting for over 50% of sales [2]. Group 1: Sales Strategy - Atropine sales are currently dominated by offline channels, with over 50% of sales coming from this segment [2]. - The company is implementing a comprehensive marketing strategy that includes partnerships with professional associations, e-commerce platforms, and pharmacy chains [2]. Group 2: Product Accessibility and Education - The company is committed to improving product accessibility and patient medication experience through ongoing academic promotion and public education on myopia prevention [2]. - Efforts are being made to enhance the pharmaceutical service system to support these initiatives [2].

Group 1 - The company, Xingqi Eye Medicine, is currently in the early communication stage with overseas partners regarding potential international expansion [2] - The company will fulfill its information disclosure obligations in accordance with relevant regulations once it reaches the information disclosure threshold [2] - Investors are advised to monitor the company's regular reports for specific sales performance details [2]

Core Viewpoint - The company currently has four production lines certified for the production of 0.01% atropine sulfate eye drops, which are sufficient to meet current market demand. Future capacity adjustments will be made based on market demand changes [1]. Group 1 - The company has four production lines with GMP certification for 0.01% atropine sulfate eye drops [1]. - Current production capacity is adequate to satisfy market demand [1]. - The company plans to adjust production capacity and layout according to changes in market demand in the future [1].

Core Viewpoint - The company has four production lines certified for GMP to produce 0.01% atropine sulfate eye drops, and its current production capacity meets market demand [1] Group 1 - The company has obtained GMP certification for four production lines [1] - The production capacity is currently sufficient to meet market demand [1]

Group 1 - The ophthalmology medical concept sector rose by 1.24%, ranking 7th among concept sectors, with 30 stocks increasing in value, including notable gainers such as People's Tongtai, Zhongsheng Pharmaceutical, and ST Zhongzhu, which hit the daily limit up [1] - The top gainers in the sector included Guanhao Biological, Innovative Medical, and Baijin Medical, with increases of 7.47%, 5.67%, and 4.75% respectively [1] - The sector experienced a net inflow of 882 million yuan from main funds, with 28 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 50 million yuan, led by Zhongsheng Pharmaceutical with a net inflow of 436 million yuan [1] Group 2 - The top stocks by net inflow ratio included People's Tongtai, Jianghe Group, and ST Zhongzhu, with net inflow ratios of 36.50%, 22.79%, and 18.25% respectively [2] - Zhongsheng Pharmaceutical had a daily increase of 10.02% with a turnover rate of 17.65%, while Heng Rui Pharmaceutical and Xingqi Eye Medicine had net inflows of 192 million yuan and 100 million yuan respectively [2][3] - The overall performance of the ophthalmology medical sector was supported by significant capital inflows, indicating strong investor interest [1][2]

Core Points - The company announced the results of the fourth vesting period for its 2021 restricted stock incentive plan, with a total of 1,080,582 shares vesting, representing 0.44% of the company's total share capital before vesting [1] - A total of 77 individuals are involved in this vesting event, with the vesting date set for November 7, 2025 [1] - The shares from this vesting will be listed and tradable on November 7, 2025, and there is no lock-up period for these restricted shares [1]